Reversible binocular visual loss in temporal association with artesunate-amodiaquine treatment in a child on mefloquine chemoprophylaxis

• Published in: Ghana medical journal 2012-09, Vol.46 (3), p.171-173
• Main Authors: Adjei, G O, Adabayeri, V M, Annobil, S H
• Format: Article
• Language: English
• Subjects: Amodiaquine - adverse effects; Anti-Inflammatory Agents - therapeutic use; Antimalarials - adverse effects; Artemisinins - adverse effects; Case Reports; Chemoprevention; Child; Dexamethasone - therapeutic use; Drug Combinations; Female; Humans; Malaria - drug therapy; Malaria - prevention & control; Mefloquine - therapeutic use; Time Factors; Vision Disorders - chemically induced; Visual Acuity
• ISSN: 0016-9560

A case of an acute reversible visual loss in a 10-year-old child who was on mefloquine prophylaxis, and was treated with artesunate-amodiaquine for an acute febrile illness diagnosed clinically as uncomplicated malaria, is reported. On admission the patient could not perceive light and had bilateral papilloedema. She was treated with dexamethasone and recovered her sight gradually over a 21-day period. There has been no previous report to our knowledge, of an association between acute visual loss and mefloquine, amodiaquine, or artesunate in the published literature, even though mefloquine is associated with blurring of vision, and antimalarials of the quinoline class have been associated with retinopathy (during long term use). While causality is difficult to ascribe in this case, it may be prudent to avoid the use of quinoline-based antimalarials for treating acute malaria in travelers taking mefloquine prophylaxis, because information on the safety of concurrent use of artemisinin combination therapies and mefloquine, or other recommended prophylactic regimens, is limited.